Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Change in Account Payables (2016 - 2025)

Historic Change in Account Payables for Karyopharm Therapeutics (KPTI) over the last 14 years, with Q4 2025 value amounting to -$1.4 million.

  • Karyopharm Therapeutics' Change in Account Payables fell 10547.34% to -$1.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$1.1 million, marking a year-over-year decrease of 15564.52%. This contributed to the annual value of -$1.1 million for FY2025, which is 15564.52% down from last year.
  • Latest data reveals that Karyopharm Therapeutics reported Change in Account Payables of -$1.4 million as of Q4 2025, which was down 10547.34% from $2.8 million recorded in Q3 2025.
  • Karyopharm Therapeutics' Change in Account Payables' 5-year high stood at $6.3 million during Q1 2023, with a 5-year trough of -$6.8 million in Q2 2023.
  • For the 5-year period, Karyopharm Therapeutics' Change in Account Payables averaged around -$22350.0, with its median value being -$703500.0 (2021).
  • Per our database at Business Quant, Karyopharm Therapeutics' Change in Account Payables tumbled by 48072.92% in 2021 and then soared by 32217.26% in 2024.
  • Karyopharm Therapeutics' Change in Account Payables (Quarter) stood at $722000.0 in 2021, then surged by 171.47% to $2.0 million in 2022, then grew by 11.22% to $2.2 million in 2023, then crashed by 131.01% to -$676000.0 in 2024, then crashed by 105.47% to -$1.4 million in 2025.
  • Its Change in Account Payables was -$1.4 million in Q4 2025, compared to $2.8 million in Q3 2025 and -$3.3 million in Q2 2025.